Under this agreement The assets. The transaction includes an initial payment of $20 million and a total value of more than
$550 million including all development, regulatory and commercial milestones, with tier royalties thereafter.
FLORENCE, Italy and CAMBRIDGE, Mass. , Jan. 13, 2025 PRNewswire- Menarini Group
(“Menarini”), a leading international pharmaceutical samoa email list 150000 contact leads and diagnostics company and Stemline
Therapeutics, Inc. (“Stemline”), a wholly own subsidiary of Menarini Group focus on bringing disease-
modifying oncology treatments to cancer patients, and Insilico Micine (“Insilico”), a clinical-stage
artificial intelligence (AI)-driven biotech company, today announc that they have enter into an
exclusive licensing agreement granting Stemline global rights to develop and commercialize a preclinical small molecule targeting a high unmet ne in oncology.
This preclinical small molecule drug, a highly selective and potentially
Best-in-class small molecule inhibitor against a broad range of solid tumor cancers, was develop with
the assistance of Insilico’s generative chemistry engine Chemistry42 and the Insilico Drug Discovery
team. This asset has successfully complet preclinical introduction to html basics development and demonstrat broad anti-tumor
activity in specific cancers.
Elcin Barker Ergun , CEO of Menarini Group , said: “We are excit to start our second collaboration with
Insilico Micine, a leader in generative AI, to create a highly selective and potentially best-in-class small
molecule targeting a variety of cancers. This asset will help us enter new areas of high unmet ne and
expand our tumor footprint, allowing us to help cancer patients with breakthrough treatments.”
“Our previous experience with Menarini Stemline has proven that the company is efficient
Agile, strategic and committ to rapidly bringing the best new treatment solutions to cancer patients,
maximizing the likelihood of program calling list success,” said Dr. Alex Zhavoronkov , Founder and CEO of
Insilico Micine. “Menarini Stemline’s strategic and visionary management is rapidly reshaping the
oncology field, and we are honor to be part of this effort that will help extend the lives of patients around the world Under this agreement.